Holen Sie sich die Stockscreener-App
14.70
0.20%
-0.01
Handel nachbörslich:
14.42
-0.28
-1.90%
Schlusskurs vom Vortag:
$14.71
Offen:
$14.57
24-Stunden-Volumen:
453.69K
Relative Volume:
0.57
Marktkapitalisierung:
$1.55B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-150.70M
KGV:
-9.4839
EPS:
-1.55
Netto-Cashflow:
$-125.67M
1W Leistung:
-3.04%
1M Leistung:
+3.09%
6M Leistung:
+19.06%
1J Leistung:
-53.87%
1-Tages-Spanne:
$14.25
$14.98
1-Wochen-Bereich:
$14.25
$16.51
52-Wochen-Spanne:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.70 | 1.55B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Goldman | Neutral |
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
What recovery options are there for Edgewise Therapeutics Inc.Quarterly Growth Report & Daily Entry Point Alerts - newser.com
How to build a custom watchlist for Edgewise Therapeutics Inc.Quarterly Profit Report & Real-Time Volume Analysis - newser.com
Key metrics from Edgewise Therapeutics Inc.’s quarterly data2025 Major Catalysts & Growth Focused Entry Reports - newser.com
Edgewise Therapeutics Inc. stock trend forecastIndex Update & Free Growth Oriented Trading Recommendations - newser.com
Building trade automation scripts for Edgewise Therapeutics Inc.July 2025 Trends & AI Powered Buy and Sell Recommendations - newser.com
Is Edgewise Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Pullbacks & Daily Volume Surge Trade Alerts - newser.com
How to use a screener to detect Edgewise Therapeutics Inc. breakoutsMarket Movers & Risk Controlled Stock Alerts - newser.com
Why Edgewise Therapeutics Inc. is moving todayQuarterly Portfolio Review & Daily Profit Focused Screening - newser.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Multi asset correlation models including Edgewise Therapeutics Inc.2025 Analyst Calls & Capital Protection Trading Alerts - newser.com
Can Edgewise Therapeutics Inc. stock beat analyst upgrades2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
What analysts say about Edgewise Therapeutics Inc stockMACD Trading Signals & Fast Growing Stocks - earlytimes.in
What drives Edgewise Therapeutics Inc stock priceHigh Frequency Trading Trends & High Return Stock Ideas - earlytimes.in
Edgewise Therapeutics (EWTX): Exploring Valuation After Positive Long-Term Data on Sevasemten in Muscular Dystrophy Trials - Sahm
How high can Edgewise Therapeutics Inc. stock goJuly 2025 Summary & Free Technical Confirmation Trade Alerts - newser.com
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.1%Here's What Happened - MarketBeat
Can a trend reversal in Edgewise Therapeutics Inc. lead to recoveryGDP Growth & Safe Entry Trade Reports - newser.com
Applying Elliott Wave Theory to Edgewise Therapeutics Inc.Portfolio Return Report & Technical Entry and Exit Tips - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress - Yahoo Finance
Edgewise Therapeutics (EWTX): Evaluating Valuation as New Long-Term Clinical Data Sparks Investor Interest - Yahoo Finance
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring A 135.53% Upside Potential - DirectorsTalk Interviews
How Investors Are Reacting To Edgewise Therapeutics (EWTX) Unveiling Long-Term Data for Sevasemten at WMS 2025 - Sahm
Edgewise Therapeutics presents muscular dystrophy research at Vienna conference - Traders Union
Tools to monitor Edgewise Therapeutics Inc. recovery probabilityWeekly Trend Report & Long-Term Growth Stock Strategies - newser.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
Edgewise Therapeutics (EWTX): Reviewing Valuation After Recent Momentum Shifts - Sahm
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by HighMark Wealth Management LLC - MarketBeat
Best data tools to analyze Edgewise Therapeutics Inc. stockTrade Entry Report & Smart Money Movement Tracker - newser.com
Will earnings trigger a reversal in Edgewise Therapeutics Inc.Weekly Trend Recap & Short-Term Swing Trade Alerts - newser.com
Edgewise Therapeutics reports inducement grants as permitted by Nasdaq listing rules - MarketScreener
Breakthrough Muscular Dystrophy Treatment: Edgewise's Sevasemten Shows Disease Stabilization in Key Trials - Stock Titan
Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet - MSN
Is Edgewise Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Set Up Real-Time Alerts – It’s Free - earlytimes.in
Edgewise Therapeutics (NASDAQ:EWTX) Raised to "Hold" at The Goldman Sachs Group - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 8.5%Here's Why - MarketBeat
The Goldman Sachs Group Begins Coverage on Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Goldman Sachs Initiates Coverage of Edgewise Therapeutics (EWTX) with Neutral Recommendation - Nasdaq
Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating By Investing.com - Investing.com Canada
Edgewise Therapeutics (NASDAQ:EWTX) Trading 8.5% HigherShould You Buy? - MarketBeat
Pattern recognition hints at Edgewise Therapeutics Inc. upsideWeekly Volume Report & Capital Protection Trading Alerts - newser.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $40.55 Average Price Target from Analysts - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 4.8%Should You Sell? - MarketBeat
Full technical analysis of Edgewise Therapeutics Inc. stockAnalyst Upgrade & Risk Adjusted Buy/Sell Alerts - newser.com
Will Edgewise Therapeutics Inc. continue its uptrendPortfolio Return Summary & High Conviction Investment Ideas - newser.com
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edgewise Therapeutics Inc-Aktie (EWTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Aug 26 '25 |
Sale |
14.60 |
100,000 |
1,459,760 |
23,400 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):